Drug Trial Radar · NCT05540327
The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
381
Actual
Start
Sep 16, 2022
Primary completion
Aug 12, 2028
Study completion Aug 12, 2028
Sponsor
- Lead sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyIndustry
- Sponsor type
- Industry
- First posted
- Sep 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 76 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the long term safety and efficacy of orally administered M5049 in participants with subacute cutaneous lupus erythematosus (SCLE), discoid lupus erythematosus (DLE) and/or systemic lupus erythematosus (SLE) who have completed the 24 week treatment period of Willow study (MS200569\_0003 \[NCT05162586\]).
Conditions
- Systemic Lupus Erythematosus
Interventions
M5049 low doseDrug
Participants will receive film-coated tablets of M5049 at a low dose orally, twice a day (BID) for up to 194 weeks.
M5049 medium doseDrug
Participants will receive film-coated tablets of M5049 at a medium dose orally, BID for up to 194 weeks.
M5049 high doseDrug
Participants will receive film-coated tablets of M5049 at a high dose orally, BID for up to 194 weeks.
PlaceboDrug
Participants will receive M5049 matching placebo orally, BID for up to 194 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Safety Profile as Assessed by Incidence of Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Adverse Event of Special Interest (AESIs)Time frame: Baseline up to Week 50 (Long Term Extension Part 1)
- Part 2: Safety Profile as Assessed by Incidence of Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Adverse Event of Special Interest (AESIs)Time frame: Baseline up to Week 194 (LTE Part 1 and LTE Prolongation Part 2))
Locations
122 sites in 22 countries. Site status is shown where the registry gives one.
The Lundquist Institute at Harbor-UCLA Medical Center
Torrance, California
Bay Area Arthritis and Osteoporosis
Brandon, Florida
Advance Medical Research Center
Miami, Florida
Dawes Fretzin Dermatology Group, LLC
Indianapolis, Indiana
AA MRC LLC Ahmed Arif Medical Research Center
Grand Blanc, Michigan
University of Minnesota
Minneapolis, Minnesota
Ohio State University - CTMO Parent
Columbus, Ohio
Ramesh C Gupta, MD
Memphis, Tennessee
Centro de Investigaciones Medicas Mar del Plata - CIM
Buenos Aires, Argentina
CINME - Centro De Investigaciones Metabolicas
Buenos Aires, Argentina
Buenos Aires Skin
Ciudad Autonoma Buenos Aires, Argentina
Hospital Militar Central Dr. Cosme Argerich
Ciudad Autonoma Buenos Aires, Argentina
Centro de Investigaciones Medicas Mar del Plata - CIM
Mar del Plata, Argentina
Instituto de Reumatologia
Mendoza, Argentina
Instituto Medico de alta Complejidad San Isidro S.A (IMAC)
San Fernando, Argentina
CER San Juan Centro Polivalente de Asistencia e Inv. Clinica
San Juan, Argentina
Centro Dermatologico Schejtman
San Miguel, Argentina
PSORIAHUE-Medicina Interdisciplinar
San Miguel, Argentina
Centro de Investigaciones Medicas Tucuman
San Miguel de Tucumán, Argentina
Investigaciones Clinicas Tucuman
San Miguel de Tucumán, Argentina
Monash Medical Centre Clayton
Clayton, Australia
Veracity Clinical Research
Woolloongabba, Australia
Santa Casa de Misericórdia de Belo Horizonte
Belo Horizonte, Brazil
Oncovida - Centro de Onco-Hematologia de Mato Grosso
Cuiabá, Brazil
Clínica SER da Bahia
Graça, Brazil
CMiP - Centro Mineiro de Pesquisa
Juiz de Fora, Brazil
Hospital Moinhos de Vento
Moinhos de Vento, Brazil
Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto - CIP - Centro Integrado de Pesquisa
São José, Brazil
CEPIC - Centro Paulista de Investigação Clínica e Serviços Médicos
São Paulo, Brazil
DCC 'Sveti Georgi' EOOD - Cardiology Office
Haskovo, Bulgaria
MC Artmed OOD
Plovdiv, Bulgaria
DCC 1 Sevlievo EOOD
Sevlievo, Bulgaria
DCC Focus 5 - MEOH OOD
Sofia, Bulgaria
Military Medical Academy - MHAT - Sofia
Sofia, Bulgaria
UMHAT "Sv. Ivan Rilski", EAD - Clinic of Rheumatology
Sofia, Bulgaria
UMHAT "Sv. Ivan Rilski", EAD - Clinica of Rheumatology
Sofia, Bulgaria
Clinica Alemana de Osorno - Corporacion de Beneficencia Osorno
Los Lagos, Chile
BioMedica Research Group - Psicomedica Clinical and Research Group
Santiago, Chile
CeCim Biocinetic
Santiago, Chile
Centro Medico Prosalud
Santiago, Chile
Showing 40 of 122 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.